(Reuters) – Pfizer and its German partner BioNTech have filed proceedings at the High Court of England & Wales seeking judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac’s European patents, according to a regulatory filing on Friday.
(Reporting by Amruta Khandekar)
